EDIT-301, Experimental Cell Therapy for SCD, Earns Rare Pediatric Disease Designation

EDIT-301, Experimental Cell Therapy for SCD, Earns Rare Pediatric Disease Designation
5
(6)

The U.S. Food and Drug Administration (FDA) has given rare pediatric disease designation to EDIT-301, a potential cell therapy for the treatment of sickle cell disease (SCD).

This designation is given to therapies that aim to treat serious or life-threatening disorders that affect fewer than 200,000 people in the U.S., primarily those younger than 18. Companies whose medications are approved after receiving this designation may be eligible to receive a priority review voucher to be used on a different product.

Editas Medicine, the company developing EDIT-301, also stated that it is planning to submit an investigational new drug (IND) application to the FDA before the end of this year, so that EDIT-301 can enter clinical testing.

“The Editas team has a bold vision to unlock the potential of CRISPR to design and develop game-changing medicines. We are making tremendous progress towards this vision with the continued development of EDIT-301, a potentially transformative medicine for the treatment of sickle cell disease, and we are pleased to receive Rare Pediatric Disease designation from the FDA for this program,” Cynthia Collins, CEO of Editas Medicine, said in a press release.

“We know patients are counting on us, and this designation is a significant milestone for the program that highlights the serious, life-threatening manifestations of sickle cell disease,” Collins said.

EDIT-301 is an investigational cell therapy made of red blood cell progenitors containing the CD34 protein — a marker of blood cell precursors — on their surface.

After being isolated from patients, these blood cell precursors are genetically modified — using the CRISPR/Cas12a (also known as Cpf1) gene-editing tool — to change a portion of the DNA sequence of the HBB gene, which is mutated in people with SCD.

Such alteration in the HBB gene ensures that red blood cells generated from these progenitor cells are able to produce high levels of fetal hemoglobin — a version of hemoglobin found in newborns that is more efficient at transporting oxygen than its adult counterpart. Also, fetal hemoglobin is able to inhibit the clumping of sickled hemoglobin, which blocks blood flow and causes pain crises in people with SCD.

By increasing the production of fetal hemoglobin, EDIT-301 is intended to provide long-term benefits to people with SCD, according to Editas.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 15
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • Adakveo
  • olinciguat for SCD
  • EMA PRIME designation for LentiGlobin
  • EDIT-301

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 6

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?